Currently, PD-1 inhibitors are considered the standard of care as adjuvant therapy in high-risk resected stage III or in metastatic stage IV melanoma patients, and tumor regression and long-term durable cancer control are possible in a high proportion of patients, compared with < 10% before the introduction of immunotherapy [5]. Here, PDCD1 is linked to neoplasm.